Johnson & Johnson corrects FY2024 operational sales guidance midpoint to $88.9B

JOHNSON & JOHNSON

2024-Q1 EPS reported $1.34 revenue$21,383,000,000

Full-year 2024 operational sales guidance midpoint revised to $88.9B from $88.0B due to typo correction.
Amendment No. 1 to Form 8-K filed April 16, 2024 corrects error in prior press release; no other changes.
Press release for Q1 2024 (period ended March 31, 2024) otherwise unchanged; specifics not provided here.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.